Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD30 CAR-T for Relapsed/Refractory CD30+ Lymphoma
NCT06850285Phase 1Recruiting
- Sponsor
- Shanxi Bethune Hospital
- Start
- Sep 2025
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of ATLCAR.CD30 T cells in CD30-positive lymphoma (3 arms), sponsored by Shanxi Bethune Hospital. Primary endpoints: Overall Response Rate at 6 months and Dose Limiting Toxicities at 28 days. Started Sep 2025; status: recruiting.
02
Drugs
ATLCAR.CD30 T cells
03
Conditions
CD30-positive lymphoma
Beyond the preview
Go deeper on NCT06850285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06850285.